Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 407

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 407
---
 |          - |     |        |          - |     |              |         - |     |        |   - |     |            |    96,896 |     |             | -           |   |     |               |      96,896 |   |
| Net loss                                                |     |                             |         - |     |        |         - |     |          |          - |     |        |          - |     |              |         - |     |        |   - |     |            |         - |     |             | (7,289,577  | ) |     |               |  (7,289,577 | ) |
| Balance at December 31, 2023                            |     |                             | 5,155,703 |     | $      | 4,077,560 |     |          | 22,764,764 |     | $      | 38,023,784 |     |              | 9,068,899 |     | $      | 907 |     | $          | 1,031,219 |     | $           | (43,089,821 | ) |     | $             | (42,057,695 | ) |

<div align='center'>See accompanying notes to financial statements.

F-53

CERo Therapeutics, Inc.

Statements of Cash Flows

For the years ended December 31, 2023 and 2022</div>

| Cash flows from operating activities:                           |     | 2023 |            |   |     | 2022 |             |   |
|:----------------------------------------------------------------|:----|:-----|-----------:|:--|:----|:-----|------------:|:--|
| Net loss                                                        |     | $    | (7,289,577 | ) |     | $    | (11,829,116 | ) |
| Adjustments to reconcile net loss to net cash used in operating 
 activities:                                                     |     |      |            |   |     |      |             |   |
| Depreciation expense                                            |     |      |    460,722 |   |     |      |     476,275 |   |
| Stock-based compensation                                        |     |      |     96,896 |   |     |      |     381,070 |   |
| Amortization of right-to-use operating lease asset              |     |      |    656,476 |